Using AI for early screening of pancreatic cancer
Artificial Intelligence-based Health Information Management System and Key Technology Study of Early Screening and Hierarchical Diagnosis and Treatment of Pancreatic Cancer
Changhai Hospital · NCT04743479
This study is testing if using artificial intelligence can help find pancreatic cancer earlier in people who are at high risk, like those with new diabetes or family history of the disease.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 5000 (estimated) |
| Ages | 50 Years to 75 Years |
| Sex | All |
| Sponsor | Changhai Hospital (other) |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT04743479 on ClinicalTrials.gov |
What this trial studies
This observational study aims to improve early detection of pancreatic cancer by utilizing artificial intelligence to identify risk factors and biomarkers in high-risk individuals. Participants will include those with new-onset diabetes, familial pancreatic cancer, inherited syndromes, pancreatic cystic neoplasms, and chronic pancreatitis. The study will involve annual laboratory tests and high-resolution MRI/CT examinations, with further evaluation of any suspicious lesions through endoscopic ultrasound. Blood samples will also be collected for future research on pancreatic cancer.
Who should consider this trial
Good fit: Ideal candidates include individuals with new-onset diabetes, familial pancreatic cancer, inherited syndromes related to pancreatic cancer, pancreatic cystic neoplasms, or chronic pancreatitis.
Not a fit: Patients who have been diagnosed with pancreatic cancer or other malignant tumors in the last 5 years will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance early diagnosis and treatment options for pancreatic cancer, potentially improving survival rates.
How similar studies have performed: While the use of AI in cancer screening is a growing field, this specific approach to pancreatic cancer screening is novel and has not been extensively tested in prior studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subject is able and willing to provide informed consent and sign an informed consent form. * Subject or authorized representative must be willing to complete a detailed questionnaire. * Subject must meet one of the following criteria: 1. New onset diabetes (diagnosed within the past 3 years) 2. Familial pancreatic cancer 3. Inherited syndromes associated with pancreatic cancer (including Hereditary pancreatitis, Familial atypical multiple mole and melanoma syndrome, Hereditary nonpolyposis colon cancer, Peutz-Jeghers syndrome, Hereditary breast and ovarian cancer syndromes, etc) 4. Pancreatic cystic neoplasm (including IPMN, MCN) 5. Chronic pancreatitis Exclusion Criteria: * Subject has been diagnosed with pancreatic cancer or other malignant tumors in the last 5 years; * Subject has any medical condition that contraindicates high-resolution MRI or CT; * Subject cannot be followed up or is participating in other clinical trials.
Where this trial is running
Shanghai
- Shanghai Changhai Hospital — Shanghai, China (RECRUITING)
Study contacts
- Study coordinator: Beilei Wang, M.D.
- Email: lilly_wang@126.com
- Phone: 13774238083
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Pancreatic Cancer, Diabetes, Familial Pancreatic Cancer, Pancreatic Cystic Neoplasm, Chronic Pancreatitis, Hereditary Pancreatitis, Screening, Early Diagnosis